User menu

An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results.

Bibliographic reference Tabernero, JM ; Humblet, Yves ; Van Cutsem, E. ; Sastre, J. ; Cervantes, A. ; et. al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results..40th Annual Meeting of the American-Society-of-Clinical-Oncology (New Orleans (La), Jun 05-08, 2004). In: Journal of Clinical Oncology, Vol. 22, no. 14, p. 248S-248S (2004)
Permanent URL http://hdl.handle.net/2078.1/61074